EUCTR2006-003137-32-IT进行中（未招募）不适用
A randomized, open label, multicenter phase II study of first line therapy with Sorafenib in association with Interleukin 2 versus Sorafenib alone in patients with unresectable and/or metastatic renal cell carcinoma (RCC) - ROSORC
I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY0 个研究点开始时间: 2007年6月12日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Signed written informed consent (approved by institutional review board / independent ethics committee)
- •2.Patient must be willing and able to comply with the protocol
- •3.Age >= 18 years
- •4.Patients with cito-hystological diagnosis of renal cell carcinoma (RCC)
- •5.If the initial diagnosis of RCC is dated more than two years ago,cito- histological confirmation of renal cell carcinoma origin of the current lesions is mandatory
- •6.Fertile women (<2 years after last menstruation) and men of childbearing potential must use effective means of contraception (oral contraceptives, intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgical sterilisation)
- •7.Measurable disease (as per RECIST criteria)
- •8.Karnofsky performance status >/= 60%
- •9.Life expectancy greater than 3 months
- •10.The required values at baseline are as follows:
- •Absolute neutrophil count >1.5 x 109 /L, Platelet count > 100 x 109 /L, Haemoglobin > 9g/dl, total bilirubin < 1.5 upper limit of normal (ULN); AST, ALT<2.5 ULN in patients without liver metastases, <5 ULN in patients with liver metastases; serum creatinine < 2.0 mg/dl, amylase and lipase <1.5 ULN
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Prior medical treatment for metastatic RCC (are allowed adjuvant or neo-adjuvant treatment but stopped almost from six months)
- •2.Major surgical procedure within 28 days prior to study treatment start
- •3.Evidence of current central nervous system (CNS) metastases or spinal cord compression. Patients must undergo a MRI or CT scan of the brain within 28 days prior to randomisation
- •4.Other malignancies within the last 5 years (other than curatively treated basal cell carcinoma of the skin and/or in situ carcinoma of the cervix, meningiomas)
- •5.Clinically significant cardiovascular disease, for example cerebrovascular accidents (<6 months), myocardial infarction (<6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure or serious cardiac arrhythmia requiring medication
- •6.Recent (within the 30 days prior to randomisation) treatment with another investigational drug or participation in another investigational study
- •7.Chronic treatment with corticosteroids (dose >10 mg/day methylprednisolone equivalent) excluding inhaled steroids.
- •8.History of other disease, metabolic dysfunction, physical examination finding or clinical laboratory finding giving reasonable suspicion of a disease condition that contraindicates use of an investigational drug or patient at high risk from treatment complications
- •9.Prior isotope treatment
- •10.PT or INR and PTT <1.5 times the Upper Normal Limit of the institution (patient who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists).
- •For patients on warfarin, close monitoring of at least weekly evaluations will be performed, until INR is stable based on a measurement at pre-dose, as defined by the local standard of care
- •11.Previous or concomitant radiotherapy in the site parameter of disease
- •12.Previous radiotherapy or other locoregional antitumoral treatment performed within 21 days before the study recruitment
- •13.Uncontrolled hypertension (>= 160 mmHg systolic and/or 90 mmHg diastolic) while receiving chronic medication
研究者
相似试验
已完成
2 期
A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1* 50%non-small cell lung cancerNL-OMON49613ovartis5
进行中（未招募）
1 期
Study of capmatinib and pembrolizumab in lung cancernon-small cell lung cancerEUCTR2019-002660-27-ESovartis Farmacéutica, S.A96
进行中（未招募）
1 期
A randomized, open label, multicenter phase II study evaluating the efficacy and safety of capmatinib (INC280) plus pembrolizumab versus pembrolizumab alone as first line treatment for locally advanced or metastatic non-small cell lung cancer with PD-L1= 50%non-small cell lung cancerEUCTR2019-002660-27-NLovartis Pharma AG96
进行中（未招募）
1 期
Study of capmatinib and pembrolizumab in lung cancernon-small cell lung cancerEUCTR2019-002660-27-GRovartis Pharma AG96
终止
2 期
Study of efficacy and safety of capmatinib in combination with pembrolizumab versus pembrolizumab alone in subjects with non-small cell lung cancer with PD-L1>= 50%on small cell lung cancer (NSCLC)JPRN-jRCT2080225053ovartis Pharma. K.K.96